PUBLICATION
[Next generation zebrafish-based drug discovery and precision medicine]
- Authors
- Tanaka, T., Koiwa, J.
- ID
- ZDB-PUB-190814-11
- Date
- 2019
- Source
- Nihon yakurigaku zasshi. Folia pharmacologica Japonica 154: 78-83 (Journal)
- Registered Authors
- Tanaka, Toshio
- Keywords
- none
- MeSH Terms
-
- Animals
- Drug Discovery/trends*
- Genomics
- Humans
- Mice
- Neoplasms
- Precision Medicine/trends*
- United States
- Xenograft Model Antitumor Assays
- Zebrafish
- PubMed
- 31406047 Full text @ Nippon Yakurigaku Zasshi
Citation
Tanaka, T., Koiwa, J. (2019) [Next generation zebrafish-based drug discovery and precision medicine]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica. 154:78-83.
Abstract
Even after entering the era of genomic drug discovery in the 21st century, development of a breakthrough therapeutic drug (first-in-class) for intractable diseases (unmet medical needs) has been extremely difficult, but to the US FDA 62% of the approved first-in-class drugs are found by phenotypic screening. The next-generation zebrafish drug discovery enables high-throughput quantitative live in vivo phenotypic screening, and has been impacting global drug discovery strategies now. Compared to severe immunodeficient mice, zebrafish is expected to become a true individualized medical tool as a clinical ex vivo diagnostic system because of the high efficiency and speed of engraftment of patient-derived cancer xenotransplantation. Phenomics-based personalized medicine with the patient-derived cancer xenograft zebrafish in addition to conventional omics platform of individualized medicine is a true next-generation precision medicine to utilize for selection of therapeutic drugs and decision of their doses for the patient, and emerging paradigm shift is realizing in this century.
Errata / Notes
article in japanese
Genes / Markers
Expression
Phenotype
Mutations / Transgenics
Human Disease / Model
Sequence Targeting Reagents
Fish
Orthology
Engineered Foreign Genes
Mapping